NCT04862767 2024-01-31
TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor
Autotelicbio
Phase 1 Completed
Clinical Trials
3 trialsNCT00019357 2015-04-29
Interleukin-2 Plus Activated White Blood Cells in Treating Patients With Cancer That Has Not Responded to Chemotherapy or Radiation Therapy
National Cancer Institute (NCI)
Phase 1 Completed
NCT00005604 2013-02-01
Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed